BRITISH JOURNAL OF HAEMATOLOGY
Scope & Guideline
Delivering High-Impact Research for Clinical Excellence
Introduction
Aims and Scopes
- Clinical Trials and Treatment Efficacy:
The journal frequently publishes results from clinical trials and observational studies that assess the efficacy and safety of new treatments for haematological malignancies, including novel agents like CAR T-cell therapies, targeted therapies, and immunotherapies. - Transfusion Medicine and Blood Disorders:
Research on transfusion practices, complications, and management of blood disorders such as sickle cell disease, thalassaemia, and immune thrombocytopenia is a core focus area, addressing both clinical and logistical aspects of transfusion medicine. - Molecular and Genetic Insights:
The journal emphasizes studies that explore the molecular and genetic basis of haematological diseases, including the impact of specific mutations on prognosis and treatment response, integrating genomics with clinical outcomes. - Patient-Centered Outcomes:
There is a strong emphasis on patient-reported outcomes and quality of life assessments in patients with haematological conditions, highlighting the importance of treatment impact on patients' daily lives. - Guidelines and Best Practices:
The journal serves as a platform for disseminating guidelines and consensus statements from leading haematology societies, ensuring that practitioners have access to the latest recommendations for diagnosis and management.
Trending and Emerging
- Novel Immunotherapies and CAR T-Cell Therapies:
There is a growing body of research focused on innovative immunotherapies, particularly CAR T-cell therapies, which are being extensively studied for their efficacy in treating various haematological malignancies. - Real-World Data and Observational Studies:
An increasing number of publications emphasize the importance of real-world evidence and observational studies, providing insights into treatment effectiveness and patient outcomes in everyday clinical settings. - Genomic and Precision Medicine:
Research into genomic profiling and precision medicine is on the rise, with studies exploring how genetic mutations and biomarkers can inform tailored treatment approaches for individual patients. - Impact of COVID-19 on Haematology Patients:
The journal has seen a surge in studies assessing the impact of COVID-19 on patients with haematological conditions, including the effects on treatment protocols and patient outcomes. - Patient-Centric Research and Quality of Life Studies:
There is an emerging trend towards research that prioritizes patient perspectives, including quality of life assessments and patient-reported outcomes, recognizing the importance of holistic care in managing haematological diseases.
Declining or Waning
- Traditional Chemotherapy Approaches:
There has been a noticeable decline in publications focused solely on traditional chemotherapy regimens for haematological malignancies, as the field increasingly shifts towards targeted therapies and immunotherapies that promise improved outcomes. - Longitudinal Studies of Established Therapies:
Research on the long-term outcomes of established therapies such as older chemotherapeutic agents has decreased, likely due to the emergence of new treatment modalities that attract more research interest. - Generalized Studies Without Specific Focus:
There appears to be less emphasis on broad, generalized studies that do not target specific haematological conditions or interventions, as the field gravitates towards more precise and targeted research. - Classic Transfusion Practices:
Although transfusion medicine remains a significant area of focus, the exploration of classic transfusion practices is waning, with more attention being given to innovative transfusion strategies and technologies. - Historical Perspectives on Haematology:
Papers focusing on historical aspects of haematology or retrospective analyses of outdated treatments are becoming less common, indicating a shift towards contemporary research that addresses current challenges.
Similar Journals
TRANSFUSION AND APHERESIS SCIENCE
Illuminating the Path of Apheresis and Transfusion ScienceTRANSFUSION AND APHERESIS SCIENCE, published by Pergamon-Elsevier Science Ltd, serves as a pivotal platform for researchers and practitioners in the fields of hematology, transfusion medicine, and apheresis. With an ISSN of 1473-0502 and an E-ISSN of 1878-1683, this peer-reviewed journal boasts a respectable Q3 ranking in the Hematology category as of 2023, positioning it within the 45th percentile among its counterparts. Operating from the United Kingdom, it provides comprehensive insights into the latest advancements and methodologies in transfusion practices and apheresis technology, crucial for enhancing patient care and therapeutic strategies. The journal's scope, covering key developments from 1996 to 2024, allows for a deep exploration of historical and emerging trends within the discipline. Moreover, its open access options facilitate widespread dissemination of research findings, fostering collaboration and innovation in the scientific community. For those dedicated to advancing knowledge in hematology, TRANSFUSION AND APHERESIS SCIENCE represents an essential resource, bridging theory and practice in this vital area of healthcare.
TRANSFUSION MEDICINE AND HEMOTHERAPY
Exploring breakthroughs in hemotherapy and patient care.TRANSFUSION MEDICINE AND HEMOTHERAPY, published by KARGER, is a prominent journal dedicated to advancing the fields of hematology and transfusion medicine. With an ISSN of 1660-3796 and E-ISSN 1660-3818, this esteemed journal has been a valuable resource for researchers and clinicians since its inception in 1973, with significant publication phases continuing into 2024. It currently holds a Q2 ranking in Hematology and a Q3 ranking in Immunology and Allergy, reflecting its impact and relevance in these critical fields. The journal features original articles, reviews, and clinical studies, presenting cutting-edge research that aids in the development of effective therapies and enhances patient care. Open access options are available, ensuring that crucial findings are accessible to a broad audience. As an important platform for dialogue and advancement in transfusion science, TRANSFUSION MEDICINE AND HEMOTHERAPY supports the global health community's efforts to improve treatment outcomes and foster innovation in medical practices.
Lancet Haematology
Catalyzing progress in the field of hematology.Lancet Haematology, published by Elsevier Science Ltd in the United Kingdom, is a premier peer-reviewed journal dedicated to advancing the field of hematology. With an impressive impact factor and listed in the Q1 category in hematology for 2023, this journal ranks #4 out of 137 in the Scopus database, boasting a 97th percentile indicating its influential role in disseminating high-quality research. Since its establishment in 2014, Lancet Haematology has provided a vital platform for researchers and clinicians to share groundbreaking studies, innovative treatment approaches, and novel therapeutic discoveries relevant to various hematological disorders. The journal does not operate under an open access model, but it offers multiple access options to facilitate engagement with its content. By bridging clinical practice and cutting-edge research, Lancet Haematology aims to foster the advancement of knowledge and improve patient outcomes in hematology, making it an essential read for professionals, researchers, and students alike.
HemaSphere
Connecting researchers, clinicians, and students in hematology.HemaSphere, published by WILEY, stands at the forefront of hematology research, offering a vital platform for the dissemination of cutting-edge findings in the field. Since its inception in 2017 and official transition to Open Access in 2018, the journal has positioned itself as a leading conduit for high-impact research, maintaining a prestigious Q1 quartile ranking in the Hematology category as of 2023. Addressed in the United States at 111 River St, Hoboken, NJ, HemaSphere aims to foster a global dialogue among researchers, clinicians, and students by providing unrestricted access to high-quality content that encompasses clinical and experimental advancements. With an array of engaging articles, reviews, and commentaries, HemaSphere contributes significantly to the advancement of hematology, ensuring that critical knowledge is readily accessible to enhance patient care and innovative research. To explore the latest developments and breakthroughs in this dynamic field, we invite scholars, professionals, and students to engage with HemaSphere and elevate their understanding of hematologic science.
BLOOD
Fostering Groundbreaking Research in Hematology.BLOOD, published by the American Society of Hematology, is a premier peer-reviewed journal in the fields of Biochemistry, Cell Biology, Hematology, and Immunology. With an impressive impact factor and ranking in the top quartiles (Q1) across multiple disciplines, BLOOD is essential reading for researchers and professionals seeking to stay updated on the latest advancements in hematology and related fields. The journal has been a cornerstone of hematological research since its inception in 1946, providing a platform for rigorous scientific inquiry and discourse. Its commitment to publishing high-quality original research, comprehensive reviews, and insightful editorials makes it a vital resource for students, practitioners, and scientists alike. By offering exceptional access to influential publications, BLOOD continues to shape the future of hematology and enhance understanding of blood-related disorders, marking its vital role in advancing both basic and clinical research.
Transfusionsmedizin
Exploring the forefront of transfusion therapy advancements.Transfusionsmedizin is a premier journal dedicated to the field of transfusion medicine, published by the renowned GEORG THIEME VERLAG KG. With an ISSN of 2191-8805 and an E-ISSN of 2191-8813, this journal serves as a vital platform for disseminating cutting-edge research and clinical advancements in blood transfusion practices. Although it operates under a subscription model, the journal is committed to high-quality peer-reviewed content that addresses contemporary challenges and innovations in transfusion therapy. By fostering dialogue among researchers, clinicians, and students, Transfusionsmedizin aims to advance patient care and enhance the safety and efficacy of transfusion practices globally. Its contributions are essential for professionals engaged in transfusion science, hematology, and related medical fields, solidifying its reputation as a critical resource for staying abreast of the latest developments in transfusion research.
Indian Journal of Hematology and Blood Transfusion
Fostering Collaboration in Hematology and Transfusion MedicineIndian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.
Egyptian Journal of Haematology
Elevating Expertise in Blood Disorders and Transfusion MedicineThe Egyptian Journal of Haematology, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of hematology, particularly within the context of Egypt and the broader Middle Eastern region. This journal is dedicated to disseminating high-quality research that explores the latest advancements in blood disorders, hematologic malignancies, and transfusion medicine. With a focus on original research, case studies, and reviews, it aims to provide a comprehensive platform for hematologists, researchers, and healthcare professionals to enhance their understanding and management of hematological conditions. Although it is not an open-access journal, the rigorous peer-review process ensures that only the most impactful studies are published, contributing to the journal's reputation in the academic community. The Egyptian Journal of Haematology serves as an essential tool for advancing knowledge, improving clinical outcomes, and fostering collaboration among experts in the field.
Blood Science
Enhancing Patient Care Through Scholarly InsightsBlood Science is a distinguished peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamic field of hematology. Since its inception, the journal has aimed to disseminate high-quality research and innovative findings that contribute to our understanding of blood-related health issues. With the ISSN 2543-6368, it offers a platform for academic discussions and breakthroughs in various subfields including hematopathology, blood disorders, and transfusion medicine. As of 2023, Blood Science is ranked in the third quartile (Q3) within the hematology category, indicating a burgeoning influence among its peers, with a Scopus rank of #101 out of 137 journals, placing it in the 26th percentile. Although it is not an open-access journal, it provides essential insights and valuable data for researchers, healthcare professionals, and students alike, enhancing the collective knowledge and practices in hematology. With a publication period spanning from 2019 to 2024, Blood Science remains committed to fostering the advancement of blood science research and enhancing patient care methodologies.
Blood Cancer Discovery
Fostering a Global Dialogue on Hematologic AdvancementsBlood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.